Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity

Toxicologic Pathology

Volumn 34, Issue 1, 2006, Pages 39-51

  Dietsch, Gregory ^a   DiPalma, Chris ^a   Eyre, Russell ^a   Pham, Tuan ^a   Poole, Karen ^a   Pefaur, Noah ^a,b   Welch, William ^a   Trueblood, Esther ^a   Kerns, William ^c   Kanaly, Suzanne ^a  

^a ELI LILLY AND COMPANY   (United States)

^b PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^c Pharma Consulting   (United States)

Author keywords

Biomarkers; Inflammation interleukin 6 (IL 6); Phosphodiesterase; Phosphodiesterase type 4 (PDE4); Rat; Toxicity; Vascular injury

Indexed keywords

BIOLOGICAL MARKER; DEXAMETHASONE; FIBRINOGEN; HAPTOGLOBIN; IC 542; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE IV INHIBITOR; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG SELECTIVITY; FEMALE; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL TRACT; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCIDENCE; INFLAMMATION; LEUKOCYTE; MESENTERY; MONKEY; NECROTIZING ARTERITIS; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; TISSUE INJURY; TOXICITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL MARKERS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOGEN; HAPTOGLOBINS; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTESTINES; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MACACA FASCICULARIS; MALE; MESENTERY; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; SPECIES SPECIFICITY; TOXICITY TESTS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 33644658285     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1080/01926230500385549     Document Type: Article

References (39)

1. Alexandre-Moreira, M. S., Takiya, C. M., de Arruda, L. B., Pascarelli, B., Gomes, R. N., Castro Faria Neto, H. C., Lima, L. M., and Barreiro, E. J. (2005). LASSBio-468: a new achiral thalidomide analogue which modulates TNF-alpha and NO production and inhibits endotoxic shock and arthritis in an animal model. Int Immunopharmacol 5, 485-94.
2. Aoki, M., Kobayashi, M., Ishikawa, J., Saita, Y., Terai, Y., Takayama, K., Miyata, K., and Yamada, T. (2000). A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrirnidin-2(1H)- one), with little emetogenic activity. J Pharmacol Exp Ther 295, 255-60.
3. Banks, R. E., Forbes, M. A., Storr, M., Higginson, J., Thompson, D., Raynes, J., Illingworth, J. M., Perren, T. J., Selby, P. J., and Whicher, J. T. (1995). The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 102, 217-23.
4. Bian, H., Zhang, J., Wu, P., Varty, L., Jia, Y., Mayhood, T., Hey, J., and Wang, P. (2004). Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkey and humans. Biochem Pharm 68, 2229-36.
5. Brideau, C., Van Staden, C., Styhler, A., Rodger, I. W., and Chan, C. C. (1999). The effects of phosphodiesterase type 4 inhibitors on tumor necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay. Br J Pharmacol 126, 979-88.
6. Bundschuh, D. S., Eltze, M., Barsig, J., Wollin, L., Hatzelman, A., and Beume, R. (2001). In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharm Exp Ther 297, 280-90.
7. Castell, J. V., Geiger, T., Gross, V., Andus, T., Walter, E., Hirano, T., Kishimoto, T., and Heinrich, P. C. (1998). Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 177, 357-61.
8. Dogterom, P., Zbinden, G., and Reznik, G. K. (1992). Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: an overview. Crit Rev Toxicol 22, 203-41.
9. Dyke, H. J., and Montana, J. G. (2002). Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 11, 1-13.
10. Gale, D. D., Landells, L. J., Spina, D., Miller, A. J., Smith, K., Nichols, T., Rotshteyn, Y., Tonelli, A., Lacouture, P., Burch, R. M., Page, C. P., and O'Conner, B. J. (2002). Pharmacokinetics and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in health volunteers. Br J Clin Pharmacol 54, 478-85.
11. Giembycz, M. A. (2001). Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic pulmonary disease. Exprt Opin Investig Drugs 10, 1361-79.
12. Giembycz, M. A., Corrigan, C. J., Seybold, J., Newton, R., and Barnes, P. J. (1996). Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118, 1945-58.
13. Giffern, P. S., Turton, J., Andrews, C. M., Barrett, P., Clarke, C. J., Fung, K. W., Munday, M. R., Roman, I. F., Smyth, R., Walshe, K., and York, M. J. (2003). Markers of experimental acute inflammation in the Wistar Han rat with particular reference to haptoglobin and C-reactive protein. Arch Toxicol 77, 392-402.
14. Griswold, D. E., Webb, E. F. Badger, A. M., Gorycki, P. D., Levandoski, P. A., Barnette, M. A., Grous, M., Christensen, S., and Torphy, T. J. (1998). SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 287, 705-11.
15. Haddad, J. J., Land, S. C., Tarnow-Mordi, W. O., Zembala, M., Kowalczyk, D., and Lauterbach, R. (2001). Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide- mediated proinflammatory cytokine (interleukin-6 and tumornecrosis factor-α) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 300, 559-66.
16. Hatzelmann, A., and Schudt, C. (2001). Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297, 267-79.
17. Hidi, R., Timmermans, S., Liu, E., Schudt, C., Dent, G., Holgate, S. T., and Djukanovic, R. (2000). Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur Respir J 15, 342-9.
18. Imai, A., Nashida, T., and Shimomura, H. (1999). Comparison of phosphodiesterase isozymes in rodent parotid glands. Comp Biochem Physiol Part B 124, 397-403.
19. Joseph, E. C., Jones, H. B., and Kerns, W. D. (1996). Characterization of coronary arterial lesions in the dog following administration of SK&F 95654, a phosphodiesterase III inhibitor. Toxicol Pathol 24, 429-35.
20. Joseph, E. C. (2000). Arterial lesions induced by phosphodiesterase III (PDE III) inhibitors and DA(1) agonists. Toxicol Lett 112-113, 537-46.
21. Joseph, E. C., Rees, J. A., and Dayan, A. D. (1996). Mesenteric arteriopathy in the rat induced by phosphodiesterase III inhibitors: an investigation of morphological, ultrastructural, and hemodynamic changes. Toxicol Pathol 24, 436-50.
22. Kajimoto, K., Hagiwara, N., Kasanuki, H., and Hosoda, S. (1997). Contribution of phosphodiesterase isozymes to the regulation of the L-type calcium current in human cardiac myocytes. Br J Pharmacol 121, 1549-56.
23. Kerns, W., Schwartz, L., Blanchard, K., Burchiel, S., Essayan, D., Fung, E., Johnson, R., Lawton, M., Louden, C., MacGregor, J., Miller, F., Nagarkatti, P., Robertson, D., Snyder, P., Thomas, H., Wagner, B., Ward, A., and Zhang, J. (2005). Drug-induced vascular injury - a quest for biomarkers. Toxicol Appl Pharmacol 203, 62-87.
24. Larson, J. L., Pino, M. V., Geiger, L. E., and Simeone, C. R. (1996). The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 78, 44-9.
25. Lipworth, B. J. (2005). Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365, 167-75.
26. Losco, P. E., Evans, E. W., Barat, S. A., Blackshear, P. E., Reyderman, L., Fine, J. S., Bober, L. A., Anthes, J. C., Mirro, E. J., and Cuss, F. M. (2004). The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys. Toxicol Pathol 32, 295-308.
27. Manning, C. D., Burman, M., Christensen, S. B., Cieslinski, L. B., Essayan, D. M., Grous, M., Torphy, T. J., and Barnette, M. S. (1999). Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 128, 1393-8.
28. Miotla, J. M., Teixeira, M. M., and Hellewell, P. G. (1998). Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Am J Respir Cell Mol Biol 18, 411-20.
29. Peppard, J. V., Smith, H. D., and Zhou, S. (1994), Kinetics of a cellular response to interleukin 6. Cell Immunol 155, 253-9.
30. Perez-Torres, S., Miro, X., Palacios, J. M., Cortez, R., Puigdomenech, P., and Mengod, G. (2000). Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography. J Chem Neuroanat 20, 349-74.
31. Perry, M. J., O'Connell, J., Walker, C., Crabbe, T., Baldock, D., Russell, A., Lumb, S., Huang, Z., Howat, D., Allen, R., Merriman, M., Walls, J., Daniel, T., Hughes, B., Laliberte, F., Higgs, G. A., and Owens, R. J. (1998). CDP840: a novel inhibitor of PDE4. Cell Biochem Biophys 29, 113-32.
32. Reimund, J. M., Raboisson, P., Pinna, G., Lugnier, C., Bourguignon, J. J., and Muller, C. D. (2001). Anti-TNF-α properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4-inhibiting properties. Biochem Biophys Res Commun. 288, 427-34.
33. Sekut, L., Yarnall, D., Stimpson, S. A., Noel, L. S., Bateman-Fite, R., Clark, R. L., Brackeen, M. F., Menius, J. A. Jr, and Connolly, K. M. (1995). Antiinflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 100, 126-32.
34. Seldon, P. M., Meja, K. K., and Giembycz, M. A. (2005). Rolipram, salbutamol and prostaglandin E2 suppress TNFalpha release from human monocytes by activating Type II cAMP-dependent protein kinase. Pulm Pharmacol Ther 8, 277-84.
35. Slim, R. M., Robertson, D. G., Albassam, M., Reily, M. D., Robosky, L., and Dethloff, L. (2002). Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats. Toxicol Appl Pharmacol 183, 108-16.
36. Trifilieff, A., Wyss, D., Walker, C., Mazzoni, L., and Hersperger, R. (2002). Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities. J Pharmacol Exp Ther 301, 241-8.
37. Turner, C. R., Esser, K. M., and Wheeldon, E. B. (1993). Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition. Circulatory Shock 39, 237-45.
38. Verde, I., Vandecasteele, G., Lezouac'h, F., and Fischmeister, R. (1999). Characterization of the cyclic mucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes. Br J Pharmacol 127, 65-74.
39. Wang, Y., Kinzie, E., Berger, F. G., Lim, S. K., and Baumann, H. (2001). Haptoglobin, an inflammation-inducible plasma protein. Redox Rep 6, 379-85.